Artivion (NYSE:AORT), a leading cardiac and vascular surgery company, announced on April 7, 2026, that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for the NEXUS™ Aortic Arch System.
The NEXUS system, developed by Artivion’s partner Endospan, is a branched endovascular stent graft designed to treat patients with aortic arch disease, including aneurysms and dissections.
The FDA approval serves as a definitive catalyst for Artivion, which now holds an exclusive 90-day option to acquire Endospan.
To facilitate the potential transaction, Artivion has already secured a $150 million delayed draw term loan specifically earmarked for the acquisition.
The regulatory clearance was supported by robust clinical data from the TRIOMPHE IDE trial.
The study demonstrated superior clinical outcomes for high-risk patients, including a 90% patient survival rate from lesion-related death at one year.
Additionally, the trial reported 90% freedom from disabling stroke and a 98% freedom from reintervention due to endoleaks within the first year post-procedure.
The NEXUS system is engineered to address the unique anatomical challenges of the aortic arch by providing a stable, branched architecture that maintains blood flow to the brain while sealing the aortic lesion.
Prior to this approval, the device had already received CE Mark in Europe, where it has been utilized in hundreds of successful procedures.
Financially, Artivion expects the integration of NEXUS to be a significant driver of top-line growth through 2027 and beyond.